Charles Explorer logo
🇬🇧

Erivedge ® (vismodegib) in advanced basocellular carcer therapy

Publication at First Faculty of Medicine |
2013

Abstract

Vismodegib is selectiv oral inhibitor of Hedghog signalling pathway. Overview presents mechanismus of action, farmakokinetic, interactions and clinical experience from ERIVANCE BCC and STEVIE studies including safety and tolerability of this drug.